v3.26.1
Segment Disclosures - Schedule of Significant Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Non-cash stock compensation $ 4,466 $ 2,042
Total operating expenses 33,235 26,825
Loss from operations (33,235) (26,825)
Interest Income 760 183
Other income (expense) (113) 1,169
Net loss (32,588) (25,473)
Reportable Segment    
Operating expenses:    
Clinical product candidates 20,921 17,781
Pre-clinical product candidates 419 114
Non-cash stock compensation 4,466 2,042
Depreciation expense 33 43
Professional fees and other segment expenses 3,029 3,118
Total operating expenses 33,235 26,825
Loss from operations (33,235) (26,825)
Interest Income 760 183
Other income (expense) (113) 1,169
Net loss (32,588) (25,473)
Reportable Segment | Research and development    
Operating expenses:    
Employee costs 2,558 2,167
Reportable Segment | General and administrative    
Operating expenses:    
Employee costs $ 1,809 $ 1,560